Hayley Barna

Who they are

Hayley Barna is a Partner at First Round Capital — co-founded Birchbox in 2010, built it to a nationally recognized beauty subscription brand, then crossed to the investing side.

Person

Hayley earned both her undergrad and MBA from Harvard, and started her career as a Senior Associate Consultant at Bain and Company — the classic consulting on-ramp. She broke from that track in 2010 to co-found Birchbox, the beauty and grooming subscription box company, serving as CEO and Board Director for years before the company became a household name in direct-to-consumer commerce. She joined First Round Capital in February 2016 when it was already an established seed-stage firm with a strong operating-first reputation, bringing rare founder credibility to a partnership bench stacked with operators from Google, Facebook, Twitter, Dropbox, and Stripe. Now a Partner based in New York, she invests across seed stage with a focus on healthcare, climate, and commerce. She ran the Angel Track community program for nearly 8 years, building a cohort of 400+ alumni — and recently hosted events specifically for NYC operators considering the founder leap, which tells you how she thinks about her role: not just check-writer but community builder. She posts on LinkedIn about early-stage investing, founder journeys, PMF, AI in startups, and healthcare innovation, and has flagged portfolio-adjacent moves in mental health (Spring Health acquiring Alma) and telehealth (Remedy Meds acquiring Thirty Madison).

Company

First Round Capital launched Fund X targeting $500 million in 2026, and made 46 investments in 2025 — including Crunched and Assured Health — maintaining a pace of 3–5 new seed investments monthly with reserve capacity for Series A follow-ons. The firm participated in Town's $55 million Series A in June 2026, a round led by Andreessen Horowitz, alongside its AI assistant product launch. First Round's portfolio has reached significant scale, with companies like Clay ($3.1B), fal ($4.5B), K2 Space ($3B), and Verkada ($5.8B) hitting multibillion-dollar valuations between 2025 and 2026. The firm operates roughly 350 people and remains philosophically committed to seed-only investing — it does not write Series A or later cheques by design.

Market

First Round Capital competes with other early-stage venture capital firms for seed-stage deals in technology, operating in a market where Q1 2026 saw record-breaking global venture funding of $300 billion, driven heavily by AI and frontier labs. Funding is concentrating in fewer companies raising larger rounds, which puts pressure on seed-stage firms to differentiate on value-add and network rather than check size. First Round's operating-first model and community infrastructure — including programs like Angel Track — are its primary points of differentiation against other generalist seed funds.

Network

Hayley's immediate network at First Round includes partners Bill Trenchard, Brett Berson, Todd Jackson, and Liz Wessel (named to Forbes Midas Brink List in 2025), alongside firm founders Josh Kopelman and Howard Morgan. Her Angel Track program has produced 400+ alumni over nearly 8 years, representing a broad operator-to-angel network across New York and beyond.

How they likely show up

  • Co-founded and ran Birchbox as CEO from 2010 → comes to investing with direct operator experience building a consumer brand; likely evaluates founders with pattern-recognition from her own founding journey, not just frameworks.
  • Ran Angel Track for nearly 8 years with 400+ alumni → invests heavily in community and long-arc relationship building, not transactional deal-flow; thinks in cohorts and networks, not one-off meetings.
  • Hosted events specifically for NYC operators considering the founder transition → signals she sees part of her role as talent development and ecosystem building, not just capital deployment.
  • Long tenure at First Round (joined February 2016, now ~10 years) → likely thinks in fund cycles and long company arcs; not chasing the next shiny thing.
  • Posts publicly on LinkedIn about healthcare M&A moves (Spring Health/Alma, Remedy Meds/Thirty Madison) → tracks sector signals actively and is comfortable sharing market views in public; responds well to substantive sector conversation.
  • Generalist seed investor with stated focus areas in healthcare, climate, and commerce → likely open to wide-ranging first conversations but will quickly pressure-test founder conviction and market insight.

Conversation tips

  • → Reference a specific portfolio company or sector move she's posted about — the Spring Health/Alma or Remedy Meds/Thirty Madison posts show she's tracking healthcare consolidation closely.
  • → Ask about the Angel Track wind-down — after nearly 8 years and 400 alumni she recently closed the program; there's a real story there about what she built and why she moved on.
  • → Don't skip the Birchbox chapter — she ran it as CEO and it's foundational to how she evaluates founders; she'll have specific, hard-won views on DTC, consumer subscription, and the gap between early traction and durable business.
  • → Engage on the operator-to-founder transition specifically if relevant — she hosts events on that exact topic and clearly has a point of view worth drawing out.

Toolbox

Openers

  • Open on the Angel Track closure — she ran it for nearly 8 years and built 400+ alumni before wrapping it up; ask what she learned about what operators actually need before making the founder leap.
  • Reference the Town Series A in June 2026 — First Round participated in that $55M round alongside a16z for an AI assistant product; it's a live, recent deal that signals where she's putting attention right now.
  • Bring up the healthcare M&A moves she's been flagging — Spring Health acquiring Alma, Remedy Meds acquiring Thirty Madison — and ask how she reads the consolidation wave in digital health from a seed investor's seat.

Discovery questions

  1. You ran Birchbox as a founder-CEO before moving to First Round — when you're evaluating an early-stage founder today, what do you look for that you couldn't have articulated before you'd actually done it?
  2. First Round is philosophically seed-only by design — how does that constraint shape which companies you choose to back, knowing you won't lead the Series A?
  3. You've been tracking healthcare consolidation closely — what does the Spring Health/Alma and Remedy Meds/Thirty Madison dynamic tell you about where the durable companies in digital health will end up?

Avoid

Don't treat her primarily as a consumer investor or reduce her to the Birchbox story — she's been a generalist seed investor across healthcare, climate, and commerce for nearly a decade and will engage on a much broader set of bets than DTC.

Make it yours

Tailor these openers to what you sell

These openers are generic. Sign in and tell Brief what you sell — it rewrites the hooks and questions around your pitch.

Sources

Brief on your next meeting?

Type any name. Get a structured pre-meeting brief in seconds.

Try Brief →

Generated by briefthecall.com from public web sources on June 5, 2026. Each claim is linked to its source above.

Automatically generated by AI from public sources. May be inaccurate or out of date. Remove or correct this profile →